{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:52:16Z","timestamp":1782139936400,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>To date, there is insufficient knowledge about crescentic glomerulonephritis (cGN), the most frequent immunologic cause of acute kidney injury in children.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Over a period of 16\u00a0years, we retrospectively analyzed kidney biopsy results, the clinical course, and laboratory data in 60 pediatric patients diagnosed with cGN.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The underlying diseases were immune complex GN (<jats:italic>n<\/jats:italic>\u2009=\u200945\/60, 75%), including IgA nephropathy (<jats:italic>n<\/jats:italic>\u2009=\u200919\/45, 42%), lupus nephritis (<jats:italic>n<\/jats:italic>\u2009=\u200910\/45, 22%), Henoch-Schoenlein purpura nephritis (<jats:italic>n<\/jats:italic>\u2009=\u20097\/45, 16%) and post-infectious GN (<jats:italic>n<\/jats:italic>\u2009=\u20097\/45, 16%), ANCA-associated pauci-immune GN (<jats:italic>n<\/jats:italic>\u2009=\u200910\/60, 17%), and anti-glomerular basement-membrane GN (<jats:italic>n<\/jats:italic>\u2009=\u20091\/60, 2%). Patient CKD stages at time of diagnosis and at a median of 362\u00a0days (range 237\u2013425) were CKD I: <jats:italic>n<\/jats:italic>\u2009=\u200913\/<jats:italic>n<\/jats:italic>\u2009=\u200929, CKD II: <jats:italic>n<\/jats:italic>\u2009=\u200915\/<jats:italic>n<\/jats:italic>\u2009=\u20099, CKD III: <jats:italic>n<\/jats:italic>\u2009=\u200916\/<jats:italic>n<\/jats:italic>\u2009=\u20097, CKD IV: <jats:italic>n<\/jats:italic>\u2009=\u20093\/n\u2009=\u20093, CKD V: <jats:italic>n<\/jats:italic>\u2009=\u200913\/<jats:italic>n<\/jats:italic>\u2009=\u20095. Course of cGN was different according to class of cGN, duration of disease from first clinical signs to diagnosis of cGN by biopsy, percentage of crescentic glomeruli, amount of tubular atrophy\/interstitial fibrosis and necrosis on renal biopsy, gender, age, nephrotic syndrome, arterial hypertension, dialysis at presentation, and relapse. Forty-eight\/60 children were treated with \u2265\u20095 (methyl-) prednisolone pulses and 53 patients received oral prednis(ol)one in combination with mycophenolate mofetil (<jats:italic>n<\/jats:italic>\u2009=\u200920), cyclosporine A (<jats:italic>n<\/jats:italic>\u2009=\u200920), and\/or cyclophosphamide (<jats:italic>n<\/jats:italic>\u2009=\u20096), rituximab (<jats:italic>n<\/jats:italic>\u2009=\u20095), azathioprine (<jats:italic>n<\/jats:italic>\u2009=\u20092), tacrolimus (<jats:italic>n<\/jats:italic>\u2009=\u20091), and plasmapheresis\/immunoadsorption (<jats:italic>n<\/jats:italic>\u2009=\u20095).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The treatment success of cGN is dependent on early diagnosis and aggressive therapy, as well as on the percentage of crescentic glomeruli on renal biopsy and on the underlying type of cGN. CsA and MMF seem to be effective alternatives to cyclophosphamide.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s00467-019-04436-y","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T09:02:47Z","timestamp":1581498167000},"page":"829-842","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Crescentic glomerulonephritis in children"],"prefix":"10.1007","volume":"35","author":[{"given":"Ulrike","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Hinrich","family":"Br\u00e4sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-6418","authenticated-orcid":false,"given":"Lars","family":"Pape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"issue":"Suppl 6","key":"4436_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/ndt\/16.suppl_6.80","volume":"16","author":"JC Jennette","year":"2001","unstructured":"Jennette JC, Thomas DB (2001) Crescentic glomerulonephritis. Nephrol Dial Transplant 16(Suppl 6):80\u201382","journal-title":"Nephrol Dial Transplant"},{"key":"4436_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.autrev.2014.02.007","volume":"13","author":"G Moroni","year":"2014","unstructured":"Moroni G, Ponticelli C (2014) Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev 13:723\u2013729","journal-title":"Autoimmun Rev"},{"key":"4436_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/ckj\/sfv008","volume":"8","author":"GH Greenhall","year":"2015","unstructured":"Greenhall GH, Salama AD (2015) What is new in the management of rapidly progressive glomerulonephritis? Clin Kidney J 8:143\u2013150","journal-title":"Clin Kidney J"},{"key":"4436_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","volume":"63","author":"JC Jennette","year":"2003","unstructured":"Jennette JC (2003) Rapidly progressive crescentic glomerulonephritis. Kidney Int 63:1164\u20131177","journal-title":"Kidney Int"},{"key":"4436_CR5","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/ki.1987.67","volume":"31","author":"DS Baldwin","year":"1987","unstructured":"Baldwin DS, Neugarten J, Feiner HD, Gluck M, Spinowitz B (1987) The existence of a protracted course in crescentic glomerulonephritis. Kidney Int 31:790\u2013794","journal-title":"Kidney Int"},{"key":"4436_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF00878354","volume":"6","author":"HM Jardim","year":"1992","unstructured":"Jardim HM, Leake J, Risdon RA, Barratt TM, Dillon MJ (1992) Crescentic glomerulonephritis in children. Pediatr Nephrol 6:231\u2013235","journal-title":"Pediatr Nephrol"},{"key":"4436_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J, IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Conference Participants (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91:1014\u20131021","journal-title":"Kidney Int"},{"key":"4436_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00103-007-0234-6","volume":"50","author":"H Neuhauser","year":"2007","unstructured":"Neuhauser H, Thamm M (2007) Blood pressure measurement in the german health interview and examination survey for children and adolescents (KiGGS). Methodology and initial results. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 50:728\u2013735","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"key":"4436_CR9","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF (2009) Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4:1832\u20131843","journal-title":"Clin J Am Soc Nephrol"},{"key":"4436_CR10","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00467-017-3628-1","volume":"32","author":"T Rauen","year":"2017","unstructured":"Rauen T, Floege J (2017) Inflammation in IgA nephropathy. Pediatr Nephrol 32:2215\u20132224","journal-title":"Pediatr Nephrol"},{"key":"4436_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00108-015-3781-1","volume":"56","author":"J Floege","year":"2015","unstructured":"Floege J (2015) Glomerulonephritides. Internist (Berl) 56:1277\u20131285 quiz 1286","journal-title":"Internist (Berl)"},{"key":"4436_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00112-004-0893-4","volume":"152","author":"M Kemper","year":"2004","unstructured":"Kemper M (2004) Primaere IgA-nephropathie und purpura schoenlein-henoch-nephritis. Monatsschrift Kinderheilkd 152:257\u2013264","journal-title":"Monatsschrift Kinderheilkd"},{"key":"4436_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00112-013-2896-5","volume":"161","author":"Arbeitsgemeinschaft fuer Paediatrische Nephrologie, (A P N )","year":"2013","unstructured":"Arbeitsgemeinschaft fuer Paediatrische Nephrologie, (A P N ) (2013) Therapieempfehlung zur lupusnephritis bei kindern und jugendlichen. Monatsschr Kinderheilkd 161:543\u2013553","journal-title":"Monatsschr Kinderheilkd"},{"key":"4436_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/ckj\/sfv020","volume":"8","author":"OO Rowaiye","year":"2015","unstructured":"Rowaiye OO, Kusztal M, Klinger M (2015) The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. Clin Kidney J 8:343\u2013350","journal-title":"Clin Kidney J"},{"key":"4436_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1055\/s-0043-106566","volume":"143","author":"M Haubitz","year":"2018","unstructured":"Haubitz M (2018) Nierenbeteiligung bei ANCA-assoziierten vaskulitiden. Dtsch Med Wochenschr 143:79\u201388","journal-title":"Dtsch Med Wochenschr"},{"key":"4436_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00467-016-3475-5","volume":"33","author":"D Noone","year":"2018","unstructured":"Noone D, Hebert D, Licht C (2018) Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement. Pediatr Nephrol 33:1\u201311","journal-title":"Pediatr Nephrol"},{"key":"4436_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s00112-013-2896-5","volume":"161","author":"M Pohl","year":"2013","unstructured":"Pohl M, Dittrich K, Ehrich JHH, Hoppe B, Kemper MJ, Klaus G, Schmitt CP, Hoyer PF, Gesellschaft fuer Paediatrische Nephrologie (G P N) (2013) Behandlung der purpura-schoenlein-henoch-nephritis bei kindern und jugendlichen. Monatsschrift Kinderheilkd 161:554\u2013553","journal-title":"Monatsschrift Kinderheilkd"},{"key":"4436_CR18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nm.2491","volume":"17","author":"G Bollee","year":"2011","unstructured":"Bollee G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg SW, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL (2011) Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 17:1242\u20131250","journal-title":"Nat Med"},{"key":"4436_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstrom","year":"2017","unstructured":"Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sorensen SS, Tesar V, Del Vecchio L, Trial Investigators NEFIGAN (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomized, placebo-controlled phase 2b trial. Lancet 389:2117\u20132127","journal-title":"Lancet"},{"key":"4436_CR20","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1681\/ASN.2016010060","volume":"28","author":"C Kuppe","year":"2017","unstructured":"Kuppe C, van Roeyen C, Leuchtle K, Kabgani N, Vogt M, Van Zandvoort M, Smeets B, Floege J, Grone HJ, Moeller MJ (2017) Investigations of glucocorticoid action in GN. J Am Soc Nephrol 28:1408\u20131420","journal-title":"J Am Soc Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-019-04436-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04436-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T13:32:43Z","timestamp":1613050363000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-019-04436-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4436"],"URL":"https:\/\/doi.org\/10.1007\/s00467-019-04436-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"12 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Hannover Medical School has agreed to this policy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}